|
Study
|
Year
|
Country
|
design
|
Men/Patients
|
Age
|
Cut-off
|
Outcome
|
|---|
|
Cho [15]
|
2018
|
Korea
|
CCS
|
214/340
|
68 ± 13
|
14.8
|
28d mortality
|
|
Han [16]
|
2018
|
China
|
RCS
|
2220/4264
|
68 (54,79)
|
NM
|
all-cause mortality
|
|
Kim [17]
|
2015
|
Korea
|
CCS
|
242/458
|
78.0 (73.8,83.0)
|
15.0
|
30d mortality
|
|
Lorente [18]
|
2014
|
Spain
|
PCS
|
201/297
|
59.5 ± 16.5
|
14.5
|
30d mortality
|
|
Ozdogan [19]
|
2015
|
Turkey
|
CCS
|
55/103
|
64 ± 14
|
16.0
|
hospital mortality
|
|
Wang [12]
|
2018
|
China
|
RCS
|
70/117
|
81.5 ± 8.3
|
14.5
|
hospital mortality
|
|
Ding [20]
|
2018
|
China
|
CCS
|
50/78
|
65.7 ± 11.5
|
14.0
|
28d mortality
|
|
Gong [21]
|
2017
|
China
|
RCS
|
121/196
|
60.88 ± 18.11
|
15.0
|
28d mortality
|
|
Li [22]
|
2019
|
USA
|
CCS
|
6626/11691
|
67.1 ± 17.1
|
NM
|
28d mortality
|
|
Shen [11]
|
2016
|
China
|
CCS
|
103/204
|
81.5 ± 7.2
|
14.18
|
30d mortality
|
|
Wang [23]
|
2015
|
China
|
PCS
|
131/213
|
71.2 ± 16.8
|
15.0
|
28d mortality
|
- Abbreviation: PCS Prospective cohort study; RCS Retrospective cohort study; CCS Case control study; NM Not mentioned
